Tax Credits for US Generic and Biosimilar Drug Production
This new law introduces tax credits for companies manufacturing generic and biosimilar drugs in the United States. The aim is to increase the availability and lower the cost of these medicines, potentially leading to reduced healthcare expenses for citizens. Additionally, the act supports investments in domestic production, which could enhance the security of drug supplies.
Key points
Companies producing generic and biosimilar drugs in the US will receive tax credits, potentially lowering drug prices.
Support for domestic drug production aims to increase availability and reduce reliance on foreign suppliers.
The act provides additional benefits for drugs with a higher percentage of US-produced components.
Expired
Citizen Poll